



Australian Government  
Department of Health



# Schedule of Pharmaceutical Benefits

Summary of Changes

**Effective 1 July 2021**



# Fees, Patient Contributions and Safety Net Thresholds

The following fees, patient contributions and safety net thresholds apply as at 1 July 2021 and are included, where applicable, in prices published in the Schedule —

|  |                                      |           |
|--|--------------------------------------|-----------|
| Dispensing Fees:                         | Ready-prepared                       | \$7.78    |
|  | Dangerous drug fee                   | \$4.82    |
|  | Extemporaneously-prepared            | \$9.82    |
|  | Allowable additional patient charge* | \$4.42    |
| Additional Fees (for safety net prices): | Ready-prepared                       | \$1.30    |
|  | Extemporaneously-prepared            | \$1.67    |
| Patient Co-payments:                     | General                              | \$41.30   |
|  | Concessional                         | \$6.60    |
| Safety Net Thresholds:                   | General                              | \$1497.20 |
|  | Concessional                         | \$316.80  |
| Safety Net Card Issue Fee:               |                                      | \$10.34   |

\* The allowable additional patient charge is a discretionary charge to general patients if a pharmaceutical item has a dispensed price for maximum quantity less than the general patient co-payment. The pharmacist may charge general patients the allowable additional fee but the fee cannot take the cost of the prescription above the general patient co-payment for the medicine. This fee does not count towards the Safety Net threshold.

# Summary of Changes

These changes to the Schedule of Pharmaceutical Benefits are effective from 1 July 2021. The Schedule is updated on the first day of each month and is available on the internet at [www.pbs.gov.au](http://www.pbs.gov.au).

## Prescriber Bag

### Alterations

#### *Alteration – Manufacturer Code*

|        |   | <i>From</i> | <i>To</i> |
|--------|---|-------------|-----------|
| 12108G | <i>Zempreon CFC-Free with dose counter – SALBUTAMOL</i> , salbutamol 100 microgram/actuation inhalation, 200 actuations | GC          | AL        |

## General Pharmaceutical Benefits

### Additions

#### *Addition – Item*

|        |   |
|--------|---|
| 12568L | <b>GUSELKUMAB</b> , guselkumab 100 mg/mL injection, 1 x 1 mL pen device ( <i>Tremfya</i> )  |
| 12590P | <b>GUSELKUMAB</b> , guselkumab 100 mg/mL injection, 1 x 1 mL syringe ( <i>Tremfya</i> )   |
| 12559B | <b>HYDROMORPHONE</b> , hydromorphone hydrochloride 1 mg/mL oral liquid, 473 mL ( <i>Hydromorphone hydrochloride oral solution, USP (Medsurge)</i> ) |
| 12582F | <b>HYDROMORPHONE</b> , hydromorphone hydrochloride 1 mg/mL oral liquid, 473 mL ( <i>Hydromorphone hydrochloride oral solution, USP (Medsurge)</i> ) |
| 12581E | <b>IMIPRAMINE</b> , imipramine hydrochloride 10 mg tablet, 100 ( <i>Imipramine (Leading)</i> )  |
| 12550M | <b>INFLIXIMAB</b> , infliximab 120 mg/mL injection, 1 mL syringe ( <i>Remsima SC</i> )  |
| 12551N | <b>INFLIXIMAB</b> , infliximab 120 mg/mL injection, 1 mL pen device ( <i>Remsima SC</i> )   |
| 12552P | <b>INFLIXIMAB</b> , infliximab 120 mg/mL injection, 1 mL syringe ( <i>Remsima SC</i> )  |
| 12553Q | <b>INFLIXIMAB</b> , infliximab 120 mg/mL injection, 1 mL syringe ( <i>Remsima SC</i> )  |
| 12554R | <b>INFLIXIMAB</b> , infliximab 120 mg/mL injection, 1 mL pen device ( <i>Remsima SC</i> )   |
| 12555T | <b>INFLIXIMAB</b> , infliximab 120 mg/mL injection, 1 mL syringe ( <i>Remsima SC</i> )  |
| 12560C | <b>INFLIXIMAB</b> , infliximab 120 mg/mL injection, 1 mL pen device ( <i>Remsima SC</i> )   |
| 12561D | <b>INFLIXIMAB</b> , infliximab 120 mg/mL injection, 1 mL syringe ( <i>Remsima SC</i> )  |
| 12566J | <b>INFLIXIMAB</b> , infliximab 120 mg/mL injection, 1 mL pen device ( <i>Remsima SC</i> )   |
| 12567K | <b>INFLIXIMAB</b> , infliximab 120 mg/mL injection, 1 mL pen device ( <i>Remsima SC</i> )   |
| 12575W | <b>INFLIXIMAB</b> , infliximab 120 mg/mL injection, 1 mL pen device ( <i>Remsima SC</i> )   |
| 12576X | <b>INFLIXIMAB</b> , infliximab 120 mg/mL injection, 1 mL syringe ( <i>Remsima SC</i> )  |
| 12577Y | <b>INFLIXIMAB</b> , infliximab 120 mg/mL injection, 1 mL pen device ( <i>Remsima SC</i> )   |
| 12584H | <b>INFLIXIMAB</b> , infliximab 120 mg/mL injection, 1 mL pen device ( <i>Remsima SC</i> )   |
| 12585J | <b>INFLIXIMAB</b> , infliximab 120 mg/mL injection, 1 mL syringe ( <i>Remsima SC</i> )  |
| 12586K | <b>INFLIXIMAB</b> , infliximab 120 mg/mL injection, 1 mL syringe ( <i>Remsima SC</i> )  |
| 12587L | <b>INFLIXIMAB</b> , infliximab 120 mg/mL injection, 1 mL pen device ( <i>Remsima SC</i> )   |

|        |   |
|--------|---|
| 12597B | <b>INFliximab</b> , infliximab 120 mg/mL injection, 1 mL syringe ( <i>Remsima SC</i> )                            |
| 12578B | <b>PANCREATIC EXTRACT</b> , pancreatic extract 35 000 units modified release capsule, 100 ( <i>Creon 35,000</i> ) |
| 12595X | <b>PANCREATIC EXTRACT</b> , pancreatic extract 35 000 units modified release capsule, 100 ( <i>Creon 35,000</i> ) |
| 12598C | <b>PROGESTERONE</b> , progesterone 200 mg capsule, 42 ( <i>Utrogestan</i> )                                       |
| 12570N | <b>SAPROPTERIN</b> , sapropterin dihydrochloride 500 mg powder for oral liquid, 30 sachets ( <i>Kuvan</i> )       |
| 12569M | <b>SAPROPTERIN</b> , sapropterin dihydrochloride 100 mg soluble tablet, 30 ( <i>Kuvan</i> )                       |
| 12579C | <b>SAPROPTERIN</b> , sapropterin dihydrochloride 100 mg soluble tablet, 30 ( <i>Kuvan</i> )                       |
| 12556W | <b>TOFACITINIB</b> , tofacitinib 5 mg tablet, 56 ( <i>Xeljanz</i> )   |
| 12557X | <b>TOFACITINIB</b> , tofacitinib 5 mg tablet, 56 ( <i>Xeljanz</i> )   |
| 12588M | <b>TOFACITINIB</b> , tofacitinib 10 mg tablet, 56 ( <i>Xeljanz</i> )  |
| 12589N | <b>TOFACITINIB</b> , tofacitinib 10 mg tablet, 56 ( <i>Xeljanz</i> )  |

**Addition – Brand**

|        |   |
|--------|---|
| 8439E  | APX-Celecoxib, TW – <b>CELECOXIB</b> , celecoxib 100 mg capsule, 60   |
| 8440F  | APX-Celecoxib, TW – <b>CELECOXIB</b> , celecoxib 200 mg capsule, 30   |
| 8840G  | Everocan, CR – <b>EVEROLIMUS</b> , everolimus 250 microgram tablet, 60  |
| 8841H  | Everocan, CR – <b>EVEROLIMUS</b> , everolimus 500 microgram tablet, 60  |
| 8842J  | Everocan, CR – <b>EVEROLIMUS</b> , everolimus 750 microgram tablet, 60  |
| 9352F  | Everocan, CR – <b>EVEROLIMUS</b> , everolimus 1 mg tablet, 60   |
| 10392Y | Ezetast, XT – <b>EZETIMIBE + ATORVASTATIN</b> , ezetimibe 10 mg + atorvastatin 10 mg tablet, 30   |
| 10393B | Ezetast, XT – <b>EZETIMIBE + ATORVASTATIN</b> , ezetimibe 10 mg + atorvastatin 20 mg tablet, 30   |
| 10377E | Ezetast, XT – <b>EZETIMIBE + ATORVASTATIN</b> , ezetimibe 10 mg + atorvastatin 40 mg tablet, 30   |
| 10376D | Ezetast, XT – <b>EZETIMIBE + ATORVASTATIN</b> , ezetimibe 10 mg + atorvastatin 80 mg tablet, 30   |
| 2449X  | APX-Gliclazide, TY – <b>GLICLAZIDE</b> , gliclazide 80 mg tablet, 100   |
| 2848X  | APX-Lamotrigine, TY – <b>LAMOTRIGINE</b> , lamotrigine 25 mg tablet, 56   |
| 2849Y  | APX-Lamotrigine, TY – <b>LAMOTRIGINE</b> , lamotrigine 50 mg tablet, 56   |
| 2850B  | APX-Lamotrigine, TY – <b>LAMOTRIGINE</b> , lamotrigine 100 mg tablet, 56  |
| 2851C  | APX-Lamotrigine, TY – <b>LAMOTRIGINE</b> , lamotrigine 200 mg tablet, 56  |
| 8797B  | TRIDOPA, TD – <b>LEVODOPA + CARBIDOPA + ENTACAPONE</b> , levodopa 50 mg + carbidopa 12.5 mg + entacapone 200 mg tablet, 100                       |
| 9344T  | TRIDOPA, TD – <b>LEVODOPA + CARBIDOPA + ENTACAPONE</b> , levodopa 75 mg + carbidopa 18.75 mg + entacapone 200 mg tablet, 100                      |
| 8798C  | TRIDOPA, TD – <b>LEVODOPA + CARBIDOPA + ENTACAPONE</b> , levodopa 100 mg + carbidopa 25 mg + entacapone 200 mg tablet, 100                        |
| 9345W  | TRIDOPA, TD – <b>LEVODOPA + CARBIDOPA + ENTACAPONE</b> , levodopa 125 mg + carbidopa 31.25 mg + entacapone 200 mg tablet, 100                     |
| 8799D  | TRIDOPA, TD – <b>LEVODOPA + CARBIDOPA + ENTACAPONE</b> , levodopa 150 mg + carbidopa 37.5 mg + entacapone 200 mg tablet, 100                      |
| 9292C  | TRIDOPA, TD – <b>LEVODOPA + CARBIDOPA + ENTACAPONE</b> , levodopa 200 mg + carbidopa 50 mg + entacapone 200 mg tablet, 100                        |
| 2147B  | APX-Olmesartan, TY – <b>OLMESARTAN</b> , olmesartan medoxomil 20 mg tablet, 30  |
| 2148C  | APX-Olmesartan, TY – <b>OLMESARTAN</b> , olmesartan medoxomil 40 mg tablet, 30  |
| 2161R  | APX-Olmesartan/HCTZ, TY – <b>OLMESARTAN MEDOXOMIL + HYDROCHLOROTHIAZIDE</b> , olmesartan medoxomil 20 mg + hydrochlorothiazide 12.5 mg tablet, 30 |
| 2166B  | APX-Olmesartan/HCTZ, TY – <b>OLMESARTAN MEDOXOMIL + HYDROCHLOROTHIAZIDE</b> , olmesartan medoxomil 40 mg + hydrochlorothiazide 12.5 mg tablet, 30 |
| 2170F  | APX-Olmesartan/HCTZ, TY – <b>OLMESARTAN MEDOXOMIL + HYDROCHLOROTHIAZIDE</b> , olmesartan medoxomil 40 mg + hydrochlorothiazide 25 mg tablet, 30   |

---

|       |   |
|-------|---|
| 2348N | <i>APO-Pregabalin, TX – PREGABALIN</i> , pregabalin 25 mg capsule, 56                 |
| 2348N | <i>Blooms The Chemist Pregabalin, IB – PREGABALIN</i> , pregabalin 25 mg capsule, 56  |
| 2335X | <i>APO-Pregabalin, TX – PREGABALIN</i> , pregabalin 75 mg capsule, 56                 |
| 2335X | <i>Blooms The Chemist Pregabalin, IB – PREGABALIN</i> , pregabalin 75 mg capsule, 56  |
| 2355Y | <i>APO-Pregabalin, TX – PREGABALIN</i> , pregabalin 150 mg capsule, 56                |
| 2355Y | <i>Blooms The Chemist Pregabalin, IB – PREGABALIN</i> , pregabalin 150 mg capsule, 56 |
| 2363J | <i>APO-Pregabalin, TX – PREGABALIN</i> , pregabalin 300 mg capsule, 56                |
| 2363J | <i>Blooms The Chemist Pregabalin, IB – PREGABALIN</i> , pregabalin 300 mg capsule, 56 |
| 2590H | <i>APX-Rosuvastatin, TY – ROSUVASTATIN</i> , rosuvastatin 5 mg tablet, 30             |
| 2606E | <i>APX-Rosuvastatin, TY – ROSUVASTATIN</i> , rosuvastatin 5 mg tablet, 30             |
| 2584B | <i>APX-Rosuvastatin, TY – ROSUVASTATIN</i> , rosuvastatin 10 mg tablet, 30            |
| 2628H | <i>APX-Rosuvastatin, TY – ROSUVASTATIN</i> , rosuvastatin 10 mg tablet, 30            |
| 2574L | <i>APX-Rosuvastatin, TY – ROSUVASTATIN</i> , rosuvastatin 20 mg tablet, 30            |
| 2609H | <i>APX-Rosuvastatin, TY – ROSUVASTATIN</i> , rosuvastatin 20 mg tablet, 30            |
| 2594M | <i>APX-Rosuvastatin, TY – ROSUVASTATIN</i> , rosuvastatin 40 mg tablet, 30            |
| 2636R | <i>APX-Rosuvastatin, TY – ROSUVASTATIN</i> , rosuvastatin 40 mg tablet, 30            |

#### **Addition – Equivalence Indicator**

|       |   |
|-------|---|
| 8840G | <i>Certican, NV – EVEROLIMUS</i> , everolimus 250 microgram tablet, 60          |
| 8841H | <i>Certican, NV – EVEROLIMUS</i> , everolimus 500 microgram tablet, 60          |
| 8842J | <i>Certican, NV – EVEROLIMUS</i> , everolimus 750 microgram tablet, 60          |
| 9352F | <i>Certican, NV – EVEROLIMUS</i> , everolimus 1 mg tablet, 60                   |
| 2420J | <i>Tofranil 10, GH – IMIPRAMINE</i> , imipramine hydrochloride 10 mg tablet, 50 |

#### **Addition – Note**

|        |   |
|--------|---|
| 11371L | <b>CABOZANTINIB</b> , cabozantinib 20 mg tablet, 30 ( <i>Cabometyx</i> )                                    |
| 11369J | <b>CABOZANTINIB</b> , cabozantinib 40 mg tablet, 30 ( <i>Cabometyx</i> )                                    |
| 11360X | <b>CABOZANTINIB</b> , cabozantinib 60 mg tablet, 30 ( <i>Cabometyx</i> )                                    |
| 11361Y | <b>GOLIMUMAB</b> , golimumab 50 mg/0.5 mL injection, 0.5 mL pen device ( <i>Simponi</i> )                   |
| 11372M | <b>GOLIMUMAB</b> , golimumab 50 mg/0.5 mL injection, 0.5 mL pen device ( <i>Simponi</i> )                   |
| 11375Q | <b>GOLIMUMAB</b> , golimumab 50 mg/0.5 mL injection, 0.5 mL pen device ( <i>Simponi</i> )                   |
| 11376R | <b>GOLIMUMAB</b> , golimumab 50 mg/0.5 mL injection, 0.5 mL pen device ( <i>Simponi</i> )                   |
| 3426H  | <b>GOLIMUMAB</b> , golimumab 50 mg/0.5 mL injection, 0.5 mL syringe ( <i>Simponi</i> )                      |
| 3428K  | <b>GOLIMUMAB</b> , golimumab 50 mg/0.5 mL injection, 0.5 mL syringe ( <i>Simponi</i> )                      |
| 3434R  | <b>GOLIMUMAB</b> , golimumab 50 mg/0.5 mL injection, 0.5 mL syringe ( <i>Simponi</i> )                      |
| 3436W  | <b>GOLIMUMAB</b> , golimumab 50 mg/0.5 mL injection, 0.5 mL syringe ( <i>Simponi</i> )                      |
| 2420J  | <b>IMIPRAMINE</b> , imipramine hydrochloride 10 mg tablet, 50 ( <i>Tofranil 10</i> )                        |
| 11983Q | <b>SAPROPTERIN</b> , sapropterin dihydrochloride 500 mg powder for oral liquid, 30 sachets ( <i>Kuvan</i> ) |

#### **Addition – Restriction**

|        |   |
|--------|---|
| 11983Q | <b>SAPROPTERIN</b> , sapropterin dihydrochloride 500 mg powder for oral liquid, 30 sachets ( <i>Kuvan</i> ) |
|--------|---|

#### **Deletions**

##### **Deletion – Item**

|       |  |
|-------|--|
| 1148K | <b>CAPTOPRIL</b> , captopril 25 mg tablet, 90 ( <i>Capoten, Captopril Sandoz</i> ) |
| 1149L | <b>CAPTOPRIL</b> , captopril 50 mg tablet, 90 ( <i>Capoten, Captopril Sandoz</i> ) |

---

***Deletion – Brand***

|       |  |
|-------|--|
| 8511Y | <i>Alendrobell 70mg, GQ – ALENDRONATE</i> , alendronate 70 mg tablet, 4  |
| 8297Q | <i>Candesartan GH, GQ – CANDESARTAN</i> , candesartan cilexetil 16 mg tablet, 30   |
| 8504N | <i>Candesartan HCT GH 16/12.5, GQ – CANDESARTAN + HYDROCHLOROTHIAZIDE</i> , candesartan cilexetil 16 mg + hydrochlorothiazide 12.5 mg tablet, 30 |
| 9314F | <i>Candesartan HCT GH 32/12.5, GQ – CANDESARTAN + HYDROCHLOROTHIAZIDE</i> , candesartan cilexetil 32 mg + hydrochlorothiazide 12.5 mg tablet, 30 |
| 8404H | <i>Irbesartan HCT GH 150/12.5, GQ – IRBESARTAN + HYDROCHLOROTHIAZIDE</i> , irbesartan 150 mg + hydrochlorothiazide 12.5 mg tablet, 30            |
| 8405J | <i>Irbesartan HCT GH 300/12.5, GQ – IRBESARTAN + HYDROCHLOROTHIAZIDE</i> , irbesartan 300 mg + hydrochlorothiazide 12.5 mg tablet, 30            |
| 2136K | <i>Irbesartan HCT GH 300/25, GQ – IRBESARTAN + HYDROCHLOROTHIAZIDE</i> , irbesartan 300 mg + hydrochlorothiazide 25 mg tablet, 30                |
| 8883M | <i>Mirtazapine GH, GQ – MIRTAZAPINE</i> , mirtazapine 45 mg tablet, 30   |
| 8627C | <i>Montelukast GH, GQ – MONTELUKAST</i> , montelukast 4 mg chewable tablet, 28   |
| 8449Q | <i>Perindopril/ Indapamide GH 4/1.25, GQ – PERINDOPRIL + INDAPAMIDE</i> , perindopril erbumine 4 mg + indapamide hemihydrate 1.25 mg tablet, 30  |
| 8313M | <i>Simvastatin generichealth, GQ – SIMVASTATIN</i> , simvastatin 80 mg tablet, 30  |
| 9245N | <i>Simvastatin generichealth, GQ – SIMVASTATIN</i> , simvastatin 80 mg tablet, 30  |

**Alterations*****Alteration – Note***

|        |   |
|--------|---|
| 12337H | <b>ADALIMUMAB</b> , adalimumab 20 mg/0.2 mL injection, 2 x 0.2 mL syringes ( <i>Humira</i> )                                |
| 12371D | <b>ADALIMUMAB</b> , adalimumab 20 mg/0.2 mL injection, 2 x 0.2 mL syringes ( <i>Humira</i> )                                |
| 12350B | <b>ADALIMUMAB</b> , adalimumab 20 mg/0.4 mL injection, 0.4 mL syringe ( <i>Amgevita</i> )                                   |
| 12351C | <b>ADALIMUMAB</b> , adalimumab 20 mg/0.4 mL injection, 0.4 mL syringe ( <i>Amgevita</i> )                                   |
| 12357J | <b>ADALIMUMAB</b> , adalimumab 20 mg/0.4 mL injection, 0.4 mL syringe ( <i>Amgevita</i> )                                   |
| 12344Q | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.4 mL injection, 6 x 0.4 mL syringes ( <i>Humira</i> )                                |
| 12346T | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.4 mL injection, 6 x 0.4 mL pen devices ( <i>Humira</i> )                             |
| 12347W | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.4 mL injection, 2 x 0.4 mL pen devices ( <i>Humira</i> )                             |
| 12358K | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.4 mL injection, 2 x 0.4 mL pen devices ( <i>Humira</i> )                             |
| 12359L | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.4 mL injection, 2 x 0.4 mL syringes ( <i>Humira</i> )                                |
| 12362P | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.4 mL injection, 2 x 0.4 mL pen devices ( <i>Humira</i> )                             |
| 12375H | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.4 mL injection, 2 x 0.4 mL pen devices ( <i>Humira</i> )                             |
| 12378L | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.4 mL injection, 2 x 0.4 mL syringes ( <i>Humira</i> )                                |
| 12382Q | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.4 mL injection, 2 x 0.4 mL syringes ( <i>Humira</i> )                                |
| 12391E | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.4 mL injection, 2 x 0.4 mL syringes ( <i>Humira</i> )                                |
| 12398M | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.4 mL injection, 2 x 0.4 mL syringes ( <i>Humira</i> )                                |
| 12412G | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.4 mL injection, 2 x 0.4 mL pen devices ( <i>Humira</i> )                             |
| 10944B | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes ( <i>Amgevita, Hadlima, Hyrimoz, Idacio</i> )    |
| 10955N | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices ( <i>Amgevita, Hadlima, Hyrimoz, Idacio</i> ) |
| 10960W | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes ( <i>Amgevita, Hadlima, Hyrimoz, Idacio</i> )    |
| 10961X | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices ( <i>Amgevita, Hadlima, Hyrimoz, Idacio</i> ) |
| 12325Q | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes ( <i>Amgevita, Hadlima, Hyrimoz, Idacio</i> )    |
| 12333D | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes ( <i>Amgevita, Hadlima, Hyrimoz, Idacio</i> )    |
| 12334E | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices ( <i>Amgevita, Hadlima, Hyrimoz, Idacio</i> ) |
| 12370C | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices ( <i>Amgevita, Hadlima, Hyrimoz, Idacio</i> ) |

---

|        |  |
|--------|--|
| 12415K | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices ( <i>Amgevita, Hadlima, Hyrimoz, Idacio</i> )        |
| 12438P | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes ( <i>Amgevita, Hadlima, Hyrimoz, Idacio</i> )           |
| 9033K  | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes ( <i>Amgevita, Hadlima, Hyrimoz, Idacio</i> )           |
| 9034L  | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes ( <i>Amgevita, Hadlima, Hyrimoz, Idacio</i> )           |
| 9101B  | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices ( <i>Amgevita, Hadlima, Hyrimoz, Idacio</i> )        |
| 9102C  | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices ( <i>Amgevita, Hadlima, Hyrimoz, Idacio</i> )        |
| 12339K | <b>ADALIMUMAB</b> , adalimumab 80 mg/0.8 mL injection, 0.8 mL syringe ( <i>Humira</i> )  |
| 12374G | <b>ADALIMUMAB</b> , adalimumab 80 mg/0.8 mL injection, 0.8 mL pen device ( <i>Humira</i> )   |
| 10238W | <b>CERTOLIZUMAB PEGOL</b> , certolizumab pegol 200 mg/mL injection, 2 x 1 mL syringes ( <i>Cimzia</i> )                            |
| 10896L | <b>CERTOLIZUMAB PEGOL</b> , certolizumab pegol 200 mg/mL injection, 2 x 1 mL syringes ( <i>Cimzia</i> )                            |
| 10909E | <b>CERTOLIZUMAB PEGOL</b> , certolizumab pegol 200 mg/mL injection, 2 x 1 mL syringes ( <i>Cimzia</i> )                            |
| 11323Y | <b>CERTOLIZUMAB PEGOL</b> , certolizumab pegol 200 mg/mL injection, 2 x 1 mL pen devices ( <i>Cimzia</i> )                         |
| 11324B | <b>CERTOLIZUMAB PEGOL</b> , certolizumab pegol 200 mg/mL injection, 2 x 1 mL pen devices ( <i>Cimzia</i> )                         |
| 11326D | <b>CERTOLIZUMAB PEGOL</b> , certolizumab pegol 200 mg/mL injection, 2 x 1 mL pen devices ( <i>Cimzia</i> )                         |
| 11207W | <b>ETANERCEPT</b> , etanercept 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack ( <i>Enbrel</i> ) |
| 9035M  | <b>ETANERCEPT</b> , etanercept 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack ( <i>Enbrel</i> ) |
| 9036N  | <b>ETANERCEPT</b> , etanercept 25 mg injection [4 vials] (&) inert substance diluent [4 x 1 mL syringes], 1 pack ( <i>Enbrel</i> ) |
| 11198J | <b>ETANERCEPT</b> , etanercept 50 mg/mL injection, 4 x 1 mL pen devices ( <i>Brenzys, Enbrel</i> )                                 |
| 11202N | <b>ETANERCEPT</b> , etanercept 50 mg/mL injection, 4 x 1 mL pen devices ( <i>Brenzys</i> )   |
| 9457R  | <b>ETANERCEPT</b> , etanercept 50 mg/mL injection, 4 x 1 mL pen devices ( <i>Brenzys, Enbrel</i> )                                 |
| 9458T  | <b>ETANERCEPT</b> , etanercept 50 mg/mL injection, 4 x 1 mL pen devices ( <i>Brenzys, Enbrel</i> )                                 |
| 11208X | <b>ETANERCEPT</b> , etanercept 50 mg/mL injection, 4 x 1 mL syringes ( <i>Brenzys, Enbrel</i> )                                    |
| 11216H | <b>ETANERCEPT</b> , etanercept 50 mg/mL injection, 4 x 1 mL syringes ( <i>Brenzys</i> )  |
| 9087G  | <b>ETANERCEPT</b> , etanercept 50 mg/mL injection, 4 x 1 mL syringes ( <i>Brenzys, Enbrel</i> )                                    |
| 9088H  | <b>ETANERCEPT</b> , etanercept 50 mg/mL injection, 4 x 1 mL syringes ( <i>Brenzys, Enbrel</i> )                                    |
| 11365E | <b>GOLIMUMAB</b> , golimumab 50 mg/0.5 mL injection, 0.5 mL pen device ( <i>Simponi</i> )  |
| 11373N | <b>GOLIMUMAB</b> , golimumab 50 mg/0.5 mL injection, 0.5 mL pen device ( <i>Simponi</i> )  |
| 3430M  | <b>GOLIMUMAB</b> , golimumab 50 mg/0.5 mL injection, 0.5 mL syringe ( <i>Simponi</i> )   |
| 3432P  | <b>GOLIMUMAB</b> , golimumab 50 mg/0.5 mL injection, 0.5 mL syringe ( <i>Simponi</i> )   |
| 11381B | <b>GOLIMUMAB</b> , golimumab 100 mg/mL injection, 1 mL pen device ( <i>Simponi</i> )   |
| 11382C | <b>GOLIMUMAB</b> , golimumab 100 mg/mL injection, 1 mL pen device ( <i>Simponi</i> )   |
| 11502J | <b>GOLIMUMAB</b> , golimumab 100 mg/mL injection, 1 mL pen device ( <i>Simponi</i> )   |
| 11623R | <b>IXEKIZUMAB</b> , ixekizumab 80 mg/mL injection, 2 x 1 mL pen devices ( <i>Taltz</i> )   |
| 10894J | <b>SECUKINUMAB</b> , secukinumab 150 mg/mL injection, 2 x 1 mL pen devices ( <i>Cosentyx</i> )                                     |
| 10895K | <b>SECUKINUMAB</b> , secukinumab 150 mg/mL injection, 1 mL pen device ( <i>Cosentyx</i> )  |
| 10898N | <b>SECUKINUMAB</b> , secukinumab 150 mg/mL injection, 1 mL pen device ( <i>Cosentyx</i> )  |
| 10899P | <b>SECUKINUMAB</b> , secukinumab 150 mg/mL injection, 2 x 1 mL pen devices ( <i>Cosentyx</i> )                                     |
| 10900Q | <b>SECUKINUMAB</b> , secukinumab 150 mg/mL injection, 1 mL pen device ( <i>Cosentyx</i> )  |
| 10901R | <b>SECUKINUMAB</b> , secukinumab 150 mg/mL injection, 2 x 1 mL pen devices ( <i>Cosentyx</i> )                                     |
| 11675L | <b>TOFACITINIB</b> , tofacitinib 5 mg tablet, 56 ( <i>Xeljanz</i> )  |
| 11690G | <b>TOFACITINIB</b> , tofacitinib 5 mg tablet, 56 ( <i>Xeljanz</i> )  |
| 10767Q | <b>USTEKINUMAB</b> , ustekinumab 45 mg/0.5 mL injection, 0.5 mL vial ( <i>Stelara</i> )  |
| 10774C | <b>USTEKINUMAB</b> , ustekinumab 45 mg/0.5 mL injection, 0.5 mL vial ( <i>Stelara</i> )  |

---

---

***Alteration – Restriction***

|        |   |
|--------|---|
| 12337H | <b>ADALIMUMAB</b> , adalimumab 20 mg/0.2 mL injection, 2 x 0.2 mL syringes ( <i>Humira</i> )                                |
| 12371D | <b>ADALIMUMAB</b> , adalimumab 20 mg/0.2 mL injection, 2 x 0.2 mL syringes ( <i>Humira</i> )                                |
| 12350B | <b>ADALIMUMAB</b> , adalimumab 20 mg/0.4 mL injection, 0.4 mL syringe ( <i>Amgevita</i> )                                   |
| 12357J | <b>ADALIMUMAB</b> , adalimumab 20 mg/0.4 mL injection, 0.4 mL syringe ( <i>Amgevita</i> )                                   |
| 12344Q | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.4 mL injection, 6 x 0.4 mL syringes ( <i>Humira</i> )                                |
| 12346T | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.4 mL injection, 6 x 0.4 mL pen devices ( <i>Humira</i> )                             |
| 12347W | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.4 mL injection, 2 x 0.4 mL pen devices ( <i>Humira</i> )                             |
| 12358K | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.4 mL injection, 2 x 0.4 mL pen devices ( <i>Humira</i> )                             |
| 12359L | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.4 mL injection, 2 x 0.4 mL syringes ( <i>Humira</i> )                                |
| 12362P | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.4 mL injection, 2 x 0.4 mL pen devices ( <i>Humira</i> )                             |
| 12375H | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.4 mL injection, 2 x 0.4 mL pen devices ( <i>Humira</i> )                             |
| 12378L | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.4 mL injection, 2 x 0.4 mL syringes ( <i>Humira</i> )                                |
| 12382Q | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.4 mL injection, 2 x 0.4 mL syringes ( <i>Humira</i> )                                |
| 12391E | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.4 mL injection, 2 x 0.4 mL syringes ( <i>Humira</i> )                                |
| 12398M | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.4 mL injection, 2 x 0.4 mL syringes ( <i>Humira</i> )                                |
| 12412G | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.4 mL injection, 2 x 0.4 mL pen devices ( <i>Humira</i> )                             |
| 10944B | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes ( <i>Amgevita, Hadlima, Hyrimoz, Idacio</i> )    |
| 10955N | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices ( <i>Amgevita, Hadlima, Hyrimoz, Idacio</i> ) |
| 10960W | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes ( <i>Amgevita, Hadlima, Hyrimoz, Idacio</i> )    |
| 10961X | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices ( <i>Amgevita, Hadlima, Hyrimoz, Idacio</i> ) |
| 12333D | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes ( <i>Amgevita, Hadlima, Hyrimoz, Idacio</i> )    |
| 12370C | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices ( <i>Amgevita, Hadlima, Hyrimoz, Idacio</i> ) |
| 9033K  | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes ( <i>Amgevita, Hadlima, Hyrimoz, Idacio</i> )    |
| 9034L  | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes ( <i>Amgevita, Hadlima, Hyrimoz, Idacio</i> )    |
| 9101B  | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices ( <i>Amgevita, Hadlima, Hyrimoz, Idacio</i> ) |
| 9102C  | <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices ( <i>Amgevita, Hadlima, Hyrimoz, Idacio</i> ) |
| 12339K | <b>ADALIMUMAB</b> , adalimumab 80 mg/0.8 mL injection, 0.8 mL syringe ( <i>Humira</i> )                                     |
| 12374G | <b>ADALIMUMAB</b> , adalimumab 80 mg/0.8 mL injection, 0.8 mL pen device ( <i>Humira</i> )                                  |
| 11371L | <b>CABOZANTINIB</b> , cabozantinib 20 mg tablet, 30 ( <i>Cabometyx</i> )  |
| 11369J | <b>CABOZANTINIB</b> , cabozantinib 40 mg tablet, 30 ( <i>Cabometyx</i> )  |
| 11360X | <b>CABOZANTINIB</b> , cabozantinib 60 mg tablet, 30 ( <i>Cabometyx</i> )  |
| 11623R | <b>IXEKIZUMAB</b> , ixekizumab 80 mg/mL injection, 2 x 1 mL pen devices ( <i>Taltz</i> )                                    |
| 11252F | <b>PAZOPANIB</b> , pazopanib 200 mg tablet, 90 ( <i>Votrient</i> )  |
| 2029T  | <b>PAZOPANIB</b> , pazopanib 200 mg tablet, 90 ( <i>Votrient</i> )  |
| 2232L  | <b>PAZOPANIB</b> , pazopanib 200 mg tablet, 30 ( <i>Votrient</i> )  |
| 11261Q | <b>PAZOPANIB</b> , pazopanib 400 mg tablet, 60 ( <i>Votrient</i> )  |
| 2030W  | <b>PAZOPANIB</b> , pazopanib 400 mg tablet, 60 ( <i>Votrient</i> )  |
| 2201W  | <b>PAZOPANIB</b> , pazopanib 400 mg tablet, 30 ( <i>Votrient</i> )  |
| 9417P  | <b>SUNITINIB</b> , sunitinib 12.5 mg capsule, 28 ( <i>Sutent</i> )  |
| 9420T  | <b>SUNITINIB</b> , sunitinib 12.5 mg capsule, 28 ( <i>Sutent</i> )  |
| 9418Q  | <b>SUNITINIB</b> , sunitinib 25 mg capsule, 28 ( <i>Sutent</i> )  |
| 9421W  | <b>SUNITINIB</b> , sunitinib 25 mg capsule, 28 ( <i>Sutent</i> )  |
| 10459L | <b>SUNITINIB</b> , sunitinib 37.5 mg capsule, 28 ( <i>Sutent</i> )  |

---

|        |  |
|--------|--|
| 10504W | <b>SUNITINIB</b> , sunitinib 37.5 mg capsule, 28 ( <i>Sutent</i> )                     |
| 9419R  | <b>SUNITINIB</b> , sunitinib 50 mg capsule, 28 ( <i>Sutent</i> )                       |
| 9422X  | <b>SUNITINIB</b> , sunitinib 50 mg capsule, 28 ( <i>Sutent</i> )                       |
| 10378F | <b>TESTOSTERONE</b> , testosterone 5% (50 mg/mL) cream, 50 mL ( <i>AndroForte 5</i> )  |
| 11675L | <b>TOFACITINIB</b> , tofacitinib 5 mg tablet, 56 ( <i>Xeljanz</i> )                    |
| 11690G | <b>TOFACITINIB</b> , tofacitinib 5 mg tablet, 56 ( <i>Xeljanz</i> )                    |
| 11979L | <b>UPADACITINIB</b> , upadacitinib 15 mg modified release tablet, 28 ( <i>Rinvoq</i> ) |

**Alteration – Manufacturer Code**

|        |  | <i>From</i> | <i>To</i> |
|--------|--|-------------|-----------|
| 10399H | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes    | OQ          | RF        |
| 10400J | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices | OQ          | RF        |
| 10412B | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes    | OQ          | RF        |
| 10413C | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices | OQ          | RF        |
| 10419J | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes    | OQ          | RF        |
| 10420K | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices | OQ          | RF        |
| 10944B | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes    | OQ          | RF        |
| 10955N | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices | OQ          | RF        |
| 10960W | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes    | OQ          | RF        |
| 10961X | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices | OQ          | RF        |
| 12325Q | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes    | OQ          | RF        |
| 12326R | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes    | OQ          | RF        |
| 12327T | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes    | OQ          | RF        |
| 12328W | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices | OQ          | RF        |
| 12329X | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices | OQ          | RF        |
| 12330Y | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices | OQ          | RF        |
| 12331B | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes    | OQ          | RF        |
| 12333D | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes    | OQ          | RF        |
| 12334E | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices | OQ          | RF        |
| 12352D | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices | OQ          | RF        |
| 12353E | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices | OQ          | RF        |
| 12356H | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices | OQ          | RF        |
| 12365T | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes    | OQ          | RF        |
| 12366W | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes    | OQ          | RF        |
| 12367X | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes    | OQ          | RF        |
| 12369B | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices | OQ          | RF        |
| 12370C | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices | OQ          | RF        |
| 12385W | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices | OQ          | RF        |
| 12386X | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices | OQ          | RF        |
| 12387Y | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes    | OQ          | RF        |
| 12388B | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices | OQ          | RF        |
| 12401Q | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices | OQ          | RF        |
| 12402R | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices | OQ          | RF        |
| 12403T | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices | OQ          | RF        |
| 12415K | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices | OQ          | RF        |

|        |   |    |    |
|--------|---|----|----|
| 12416L | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes                             | OQ | RF |
| 12420Q | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices                          | OQ | RF |
| 12434K | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes                             | OQ | RF |
| 12437N | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes                             | OQ | RF |
| 12438P | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes                             | OQ | RF |
| 5281Y  | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes                             | OQ | RF |
| 5282B  | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices                          | OQ | RF |
| 5283C  | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes                             | OQ | RF |
| 5284D  | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices                          | OQ | RF |
| 8737W  | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes                             | OQ | RF |
| 8741C  | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes                             | OQ | RF |
| 8963R  | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes                             | OQ | RF |
| 8964T  | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes                             | OQ | RF |
| 8965W  | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices                          | OQ | RF |
| 8966X  | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices                          | OQ | RF |
| 9033K  | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes                             | OQ | RF |
| 9034L  | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes                             | OQ | RF |
| 9077R  | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes                             | OQ | RF |
| 9078T  | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes                             | OQ | RF |
| 9099X  | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices                          | OQ | RF |
| 9100Y  | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices                          | OQ | RF |
| 9101B  | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices                          | OQ | RF |
| 9102C  | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices                          | OQ | RF |
| 9103D  | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices                          | OQ | RF |
| 9104E  | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices                          | OQ | RF |
| 9188N  | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes                             | OQ | RF |
| 9189P  | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes                             | OQ | RF |
| 9190Q  | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices                          | OQ | RF |
| 9191R  | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices                          | OQ | RF |
| 9425C  | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes                             | OQ | RF |
| 9426D  | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices                          | OQ | RF |
| 9427E  | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes                             | OQ | RF |
| 9428F  | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices                          | OQ | RF |
| 8456C  | Seroquel – <b>QUETIAPINE</b> , quetiapine 25 mg tablet, 60  | AP | AL |
| 9202H  | Seroquel XR – <b>QUETIAPINE</b> , quetiapine 50 mg modified release tablet, 60  | AP | AL |
| 8457D  | Seroquel – <b>QUETIAPINE</b> , quetiapine 100 mg tablet, 90   | AP | AL |
| 5458G  | Seroquel XR – <b>QUETIAPINE</b> , quetiapine 150 mg modified release tablet, 60   | AP | AL |
| 8458E  | Seroquel – <b>QUETIAPINE</b> , quetiapine 200 mg tablet, 60   | AP | AL |
| 9203J  | Seroquel XR – <b>QUETIAPINE</b> , quetiapine 200 mg modified release tablet, 60   | AP | AL |
| 8580N  | Seroquel – <b>QUETIAPINE</b> , quetiapine 300 mg tablet, 60   | AP | AL |
| 9204K  | Seroquel XR – <b>QUETIAPINE</b> , quetiapine 300 mg modified release tablet, 60   | AP | AL |
| 9205L  | Seroquel XR – <b>QUETIAPINE</b> , quetiapine 400 mg modified release tablet, 60   | AP | AL |
| 12109H | Zempreon CFC-Free with dose counter – <b>SALBUTAMOL</b> , salbutamol 100 microgram/actuation inhalation, 200 actuations | GC | AL |

---

## **Alteration – Number of Repeats**

|        |   | <i>From</i> | <i>To</i> |
|--------|---|-------------|-----------|
| 10378F | TESTOSTERONE, testosterone 5% (50 mg/mL) cream, 50 mL ( <i>AndroForte 5</i> ) | 6           | 1         |

## **Supply Only**

From 1 November 2020 when a product is deleted from the Schedule it may now be available under new Supply Only rules. Supply Only items/brands are available on the Schedule for dispensing but not for prescribing, usually for a period of up to 12 months from when it is deleted.

Substitution of Supply Only items/brands with products flagged as "equivalent for substitution" still apply as specified in the Schedule at the time the script was written. Further information on Supply Only arrangements is available at [www.pbs.gov.au](http://www.pbs.gov.au)

### ***Supply Only commencing July 2021***

|        |  |
|--------|--|
| 8594H  | <i>Amisulpride Sandoz, SZ – AMISULPRIDE</i> , amisulpride 100 mg tablet, 30  |
| 8595J  | <i>Amisulpride Sandoz, SZ – AMISULPRIDE</i> , amisulpride 200 mg tablet, 60  |
| 8596K  | <i>Amisulpride Sandoz, SZ – AMISULPRIDE</i> , amisulpride 400 mg tablet, 60  |
| 11998L | <i>Amoxicillin Sandoz, SZ – AMOXICILLIN</i> , amoxicillin 250 mg capsule, 20   |
| 1884E  | <i>Amoxicillin Sandoz, SZ – AMOXICILLIN</i> , amoxicillin 250 mg capsule, 20   |
| 3301R  | <i>Amoxicillin Sandoz, SZ – AMOXICILLIN</i> , amoxicillin 250 mg capsule, 20   |
| 11963P | <i>Cefalexin Sandoz, SZ – CEFALEXIN</i> , cefalexin 250 mg capsule, 20   |
| 2655R  | <i>Cefalexin Sandoz, SZ – CEFALEXIN</i> , cefalexin 250 mg capsule, 20   |
| 3058Y  | <i>Cefalexin Sandoz, SZ – CEFALEXIN</i> , cefalexin 250 mg capsule, 20   |
| 3317N  | <i>Cefalexin Sandoz, SZ – CEFALEXIN</i> , cefalexin 250 mg capsule, 20   |
| 1269T  | <i>Androcur, BN – CYPROTERONE</i> , cyproterone acetate 50 mg tablet, 20   |
| 8180M  | <i>Roferon-A–INTERFERON ALFA-2A</i> , interferon alfa-2a 3 million units (11.111 microgram)/0.5 mL injection, 0.5 mL syringe |
| 8181N  | <i>Roferon-A–INTERFERON ALFA-2A</i> , interferon alfa-2a 3 million units (11.111 microgram)/0.5 mL injection, 0.5 mL syringe |
| 8184R  | <i>Roferon-A–INTERFERON ALFA-2A</i> , interferon alfa-2a 9 million units (33.333 microgram)/0.5 mL injection, 0.5 mL syringe |
| 8553E  | <i>Roferon-A–INTERFERON ALFA-2A</i> , interferon alfa-2a 9 million units (33.333 microgram)/0.5 mL injection, 0.5 mL syringe |
| 1900B  | <i>Mohexal, HX – MOCLOBEMIDE</i> , moclobemide 150 mg tablet, 60   |
| 8363E  | <i>Evifyne, EL – RALOXIFENE</i> , raloxifene hydrochloride 60 mg tablet, 28  |

## **Advance Notices**

### **1 August 2021**

#### ***Deletion – Brand***

|        |  |
|--------|--|
| 8189B  | <i>Glucobay 100, BN – ACARBOSE</i> , acarbose 100 mg tablet, 90  |
| 10888C | <i>Bydureon, AP – EXENATIDE</i> , exenatide 2 mg modified release injection [1 chamber] (& inert substance diluent [1 chamber], 4 dual chamber pen devices |
| 1944H  | <i>Ramace 1.25 mg, AV – RAMIPRIL</i> , ramipril 1.25 mg tablet, 30   |
| 1945J  | <i>Ramace 2.5 mg, AV – RAMIPRIL</i> , ramipril 2.5 mg tablet, 30   |
| 1946K  | <i>Ramace 5 mg, AV – RAMIPRIL</i> , ramipril 5 mg tablet, 30   |
| 8470T  | <i>Ramace 10 mg, AV – RAMIPRIL</i> , ramipril 10 mg capsule, 30  |

### **1 October 2021**

#### ***Deletion – Brand***

|        |  |
|--------|--|
| 10703H | <i>Mabthera SC, RO – RITUXIMAB</i> , rituximab 1.4 g/11.7 mL injection, 11.7 mL vial |
| 10709P | <i>Mabthera SC, RO – RITUXIMAB</i> , rituximab 1.4 g/11.7 mL injection, 11.7 mL vial |
| 10719E | <i>Mabthera SC, RO – RITUXIMAB</i> , rituximab 1.4 g/11.7 mL injection, 11.7 mL vial |
| 10742J | <i>Mabthera SC, RO – RITUXIMAB</i> , rituximab 1.4 g/11.7 mL injection, 11.7 mL vial |

11988Y *Mabthera SC, RO – RITUXIMAB*, rituximab 1.4 g/11.7 mL injection, 11.7 mL vial

**1 January 2022**

**Deletion – Brand**

11050N *Lynparza, AP – OLAPARIB*, olaparib 50 mg capsule, 4 x 112

## Palliative Care

### Additions

#### Addition – Item

12565H **HYDROMORPHONE**, hydromorphone hydrochloride 1 mg/mL oral liquid, 473 mL (*Hydromorphone hydrochloride oral solution, USP (Medsurge)*)

## Highly Specialised Drugs Program (Private Hospital)

### Additions

#### Addition – Brand

6459Y *Everocan, CR – EVEROLIMUS*, everolimus 250 microgram tablet, 60

6460B *Everocan, CR – EVEROLIMUS*, everolimus 500 microgram tablet, 60

6461C *Everocan, CR – EVEROLIMUS*, everolimus 750 microgram tablet, 60

9582H *Everocan, CR – EVEROLIMUS*, everolimus 1 mg tablet, 60

10566D *Octreotide Depot, TB – OCTREOTIDE*, octreotide 10 mg modified release injection [1 vial] (&) inert substance diluent [2 mL syringe], 1 pack

10549F *Octreotide Depot, TB – OCTREOTIDE*, octreotide 20 mg modified release injection [1 vial] (&) inert substance diluent [2 mL syringe], 1 pack

10558Q *Octreotide Depot, TB – OCTREOTIDE*, octreotide 30 mg modified release injection [1 vial] (&) inert substance diluent [2 mL syringe], 1 pack

11894B *Octreotide Depot, TB – OCTREOTIDE*, octreotide 30 mg modified release injection [1 vial] (&) inert substance diluent [2 mL syringe], 1 pack

#### Addition – Equivalence Indicator

6459Y *Certican, NV – EVEROLIMUS*, everolimus 250 microgram tablet, 60

6460B *Certican, NV – EVEROLIMUS*, everolimus 500 microgram tablet, 60

6461C *Certican, NV – EVEROLIMUS*, everolimus 750 microgram tablet, 60

9582H *Certican, NV – EVEROLIMUS*, everolimus 1 mg tablet, 60

10566D *Sandostatin LAR, NV – OCTREOTIDE*, octreotide 10 mg modified release injection [1 vial] (&) inert substance diluent [2 mL syringe], 1 pack

10549F *Sandostatin LAR, NV – OCTREOTIDE*, octreotide 20 mg modified release injection [1 vial] (&) inert substance diluent [2 mL syringe], 1 pack

10558Q *Sandostatin LAR, NV – OCTREOTIDE*, octreotide 30 mg modified release injection [1 vial] (&) inert substance diluent [2 mL syringe], 1 pack

11894B *Sandostatin LAR, NV – OCTREOTIDE*, octreotide 30 mg modified release injection [1 vial] (&) inert substance diluent [2 mL syringe], 1 pack

### Deletions

#### Deletion – Item

12030E **MEPOLIZUMAB**, mepolizumab 100 mg/mL injection, 1 mL pen device (*Nucala*)

## Alterations

### Alteration – Note

11504L **BENRALIZUMAB**, benralizumab 30 mg/mL injection, 1 mL syringe (*Fasenra*)

11523L **BENRALIZUMAB**, benralizumab 30 mg/mL injection, 1 mL syringe (*Fasenra*)

11847M **BENRALIZUMAB**, benralizumab 30 mg/mL injection, 1 mL syringe (*Fasenra*)

---

|        |   |
|--------|---|
| 11996J | <b>BENRALIZUMAB</b> , benralizumab 30 mg/mL injection, 1 mL pen device ( <i>Fasenra Pen</i> )     |
| 11997K | <b>BENRALIZUMAB</b> , benralizumab 30 mg/mL injection, 1 mL pen device ( <i>Fasenra Pen</i> )     |
| 11999M | <b>BENRALIZUMAB</b> , benralizumab 30 mg/mL injection, 1 mL pen device ( <i>Fasenra Pen</i> )     |
| 12313C | <b>DUPILUMAB</b> , dupilumab 200 mg/1.14 mL injection, 2 x 1.14 mL syringes ( <i>Dupixent</i> )   |
| 12316F | <b>DUPILUMAB</b> , dupilumab 200 mg/1.14 mL injection, 2 x 1.14 mL syringes ( <i>Dupixent</i> )   |
| 12294C | <b>DUPILUMAB</b> , dupilumab 300 mg/2 mL injection, 2 x 2 mL syringes ( <i>Dupixent</i> )         |
| 12310X | <b>DUPILUMAB</b> , dupilumab 300 mg/2 mL injection, 2 x 2 mL syringes ( <i>Dupixent</i> )         |
| 10184B | <b>INFLIXIMAB</b> , infliximab 100 mg injection, 1 vial ( <i>Inflectra, Remicade, Renflexis</i> ) |
| 11498E | <b>INFLIXIMAB</b> , infliximab 100 mg injection, 1 vial ( <i>Inflectra, Remicade, Renflexis</i> ) |
| 11515C | <b>INFLIXIMAB</b> , infliximab 100 mg injection, 1 vial ( <i>Inflectra, Renflexis</i> )           |
| 11796W | <b>INFLIXIMAB</b> , infliximab 100 mg injection, 1 vial ( <i>Inflectra, Renflexis</i> )           |
| 11797X | <b>INFLIXIMAB</b> , infliximab 100 mg injection, 1 vial ( <i>Inflectra, Remicade, Renflexis</i> ) |
| 6496X  | <b>INFLIXIMAB</b> , infliximab 100 mg injection, 1 vial ( <i>Inflectra, Remicade, Renflexis</i> ) |
| 12043W | <b>MEPOLIZUMAB</b> , mepolizumab 100 mg/mL injection, 1 mL pen device ( <i>Nucala</i> )           |
| 12051G | <b>MEPOLIZUMAB</b> , mepolizumab 100 mg/mL injection, 1 mL pen device ( <i>Nucala</i> )           |
| 12052H | <b>MEPOLIZUMAB</b> , mepolizumab 100 mg/mL injection, 1 mL pen device ( <i>Nucala</i> )           |
| 11003D | <b>MEPOLIZUMAB</b> , mepolizumab 100 mg injection, 1 vial ( <i>Nucala</i> )                       |
| 11014Q | <b>MEPOLIZUMAB</b> , mepolizumab 100 mg injection, 1 vial ( <i>Nucala</i> )                       |
| 11829N | <b>MEPOLIZUMAB</b> , mepolizumab 100 mg injection, 1 vial ( <i>Nucala</i> )                       |
| 10110D | <b>OMALIZUMAB</b> , omalizumab 75 mg/0.5 mL injection, 0.5 mL syringe ( <i>Xolair</i> )           |
| 11826K | <b>OMALIZUMAB</b> , omalizumab 75 mg/0.5 mL injection, 0.5 mL syringe ( <i>Xolair</i> )           |
| 11840E | <b>OMALIZUMAB</b> , omalizumab 75 mg/0.5 mL injection, 0.5 mL syringe ( <i>Xolair</i> )           |
| 10122R | <b>OMALIZUMAB</b> , omalizumab 150 mg/mL injection, 1 mL syringe ( <i>Xolair</i> )                |
| 11825J | <b>OMALIZUMAB</b> , omalizumab 150 mg/mL injection, 1 mL syringe ( <i>Xolair</i> )                |
| 11864K | <b>OMALIZUMAB</b> , omalizumab 150 mg/mL injection, 1 mL syringe ( <i>Xolair</i> )                |
| 10398G | <b>VEDOLIZUMAB</b> , vedolizumab 300 mg injection, 1 vial ( <i>Entyvio</i> )                      |

#### ***Alteration – Restriction***

|        |   |
|--------|---|
| 11504L | <b>BENRALIZUMAB</b> , benralizumab 30 mg/mL injection, 1 mL syringe ( <i>Fasenra</i> )          |
| 11523L | <b>BENRALIZUMAB</b> , benralizumab 30 mg/mL injection, 1 mL syringe ( <i>Fasenra</i> )          |
| 11847M | <b>BENRALIZUMAB</b> , benralizumab 30 mg/mL injection, 1 mL syringe ( <i>Fasenra</i> )          |
| 11996J | <b>BENRALIZUMAB</b> , benralizumab 30 mg/mL injection, 1 mL pen device ( <i>Fasenra Pen</i> )   |
| 11997K | <b>BENRALIZUMAB</b> , benralizumab 30 mg/mL injection, 1 mL pen device ( <i>Fasenra Pen</i> )   |
| 11999M | <b>BENRALIZUMAB</b> , benralizumab 30 mg/mL injection, 1 mL pen device ( <i>Fasenra Pen</i> )   |
| 12313C | <b>DUPILUMAB</b> , dupilumab 200 mg/1.14 mL injection, 2 x 1.14 mL syringes ( <i>Dupixent</i> ) |
| 12316F | <b>DUPILUMAB</b> , dupilumab 200 mg/1.14 mL injection, 2 x 1.14 mL syringes ( <i>Dupixent</i> ) |
| 12294C | <b>DUPILUMAB</b> , dupilumab 300 mg/2 mL injection, 2 x 2 mL syringes ( <i>Dupixent</i> )       |
| 12310X | <b>DUPILUMAB</b> , dupilumab 300 mg/2 mL injection, 2 x 2 mL syringes ( <i>Dupixent</i> )       |
| 12043W | <b>MEPOLIZUMAB</b> , mepolizumab 100 mg/mL injection, 1 mL pen device ( <i>Nucala</i> )         |
| 12051G | <b>MEPOLIZUMAB</b> , mepolizumab 100 mg/mL injection, 1 mL pen device ( <i>Nucala</i> )         |
| 12052H | <b>MEPOLIZUMAB</b> , mepolizumab 100 mg/mL injection, 1 mL pen device ( <i>Nucala</i> )         |
| 11003D | <b>MEPOLIZUMAB</b> , mepolizumab 100 mg injection, 1 vial ( <i>Nucala</i> )                     |
| 11014Q | <b>MEPOLIZUMAB</b> , mepolizumab 100 mg injection, 1 vial ( <i>Nucala</i> )                     |
| 11829N | <b>MEPOLIZUMAB</b> , mepolizumab 100 mg injection, 1 vial ( <i>Nucala</i> )                     |
| 10110D | <b>OMALIZUMAB</b> , omalizumab 75 mg/0.5 mL injection, 0.5 mL syringe ( <i>Xolair</i> )         |

|        |   |
|--------|---|
| 11826K | <b>OMALIZUMAB</b> , omalizumab 75 mg/0.5 mL injection, 0.5 mL syringe ( <i>Xolair</i> ) |
| 11840E | <b>OMALIZUMAB</b> , omalizumab 75 mg/0.5 mL injection, 0.5 mL syringe ( <i>Xolair</i> ) |
| 10122R | <b>OMALIZUMAB</b> , omalizumab 150 mg/mL injection, 1 mL syringe ( <i>Xolair</i> )      |
| 11825J | <b>OMALIZUMAB</b> , omalizumab 150 mg/mL injection, 1 mL syringe ( <i>Xolair</i> )      |
| 11864K | <b>OMALIZUMAB</b> , omalizumab 150 mg/mL injection, 1 mL syringe ( <i>Xolair</i> )      |

#### ***Alteration – Manufacturer Code***

|        |  | <i>From</i> | <i>To</i> |
|--------|--|-------------|-----------|
| 12368Y | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices | OQ          | RF        |
| 12384T | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes    | OQ          | RF        |
| 9679K  | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL syringes    | OQ          | RF        |
| 9680L  | <i>Hadlima</i> – <b>ADALIMUMAB</b> , adalimumab 40 mg/0.8 mL injection, 2 x 0.8 mL pen devices | OQ          | RF        |
| 10263E | <i>Kineret</i> – <b>ANAKINRA</b> , anakinra 100 mg/0.67 mL injection, 28 x 0.67 mL syringes    | FK          | ZO        |

#### **Supply Only**

From 1 November 2020 when a product is deleted from the Schedule it may now be available under new Supply Only rules. Supply Only items/brands are available on the Schedule for dispensing but not for prescribing, usually for a period of up to 12 months from when it is deleted.

Substitution of Supply Only items/brands with products flagged as "equivalent for substitution" still apply as specified in the Schedule at the time the script was written. Further information on Supply Only arrangements is available at [www.pbs.gov.au](http://www.pbs.gov.au)

#### ***Supply Only commencing July 2021***

|       |   |
|-------|---|
| 6210W | <i>Roferon-A</i> – <b>INTERFERON ALFA-2A</b> , interferon alfa-2a 3 million units (11.111 microgram)/0.5 mL injection, 0.5 mL syringe |
| 6213B | <i>Roferon-A</i> – <b>INTERFERON ALFA-2A</b> , interferon alfa-2a 9 million units (33.333 microgram)/0.5 mL injection, 0.5 mL syringe |

#### ***Advance Notices***

**1 August 2021**

##### ***Deletion – Brand***

|       |  |
|-------|--|
| 6357N | <i>Valcyte</i> , RO – <b>VALGANCICLOVIR</b> , valganciclovir 450 mg tablet, 60 |
|-------|--|

## **Highly Specialised Drugs Program (Community Access)**

### **Additions**

#### ***Addition – Brand***

|        |  |
|--------|--|
| 11501H | <i>Octreotide Depot</i> , TB – <b>OCTREOTIDE</b> , octreotide 10 mg modified release injection [1 vial] (&) inert substance diluent [2 mL syringe], 1 pack |
| 11537F | <i>Octreotide Depot</i> , TB – <b>OCTREOTIDE</b> , octreotide 20 mg modified release injection [1 vial] (&) inert substance diluent [2 mL syringe], 1 pack |
| 11512X | <i>Octreotide Depot</i> , TB – <b>OCTREOTIDE</b> , octreotide 30 mg modified release injection [1 vial] (&) inert substance diluent [2 mL syringe], 1 pack |
| 11896D | <i>Octreotide Depot</i> , TB – <b>OCTREOTIDE</b> , octreotide 30 mg modified release injection [1 vial] (&) inert substance diluent [2 mL syringe], 1 pack |

#### ***Addition – Equivalence Indicator***

|        |   |
|--------|---|
| 11501H | <i>Sandostatin LAR</i> , NV – <b>OCTREOTIDE</b> , octreotide 10 mg modified release injection [1 vial] (&) inert substance diluent [2 mL syringe], 1 pack |
| 11537F | <i>Sandostatin LAR</i> , NV – <b>OCTREOTIDE</b> , octreotide 20 mg modified release injection [1 vial] (&) inert substance diluent [2 mL syringe], 1 pack |
| 11512X | <i>Sandostatin LAR</i> , NV – <b>OCTREOTIDE</b> , octreotide 30 mg modified release injection [1 vial] (&) inert substance diluent [2 mL syringe], 1 pack |
| 11896D | <i>Sandostatin LAR</i> , NV – <b>OCTREOTIDE</b> , octreotide 30 mg modified release injection [1 vial] (&) inert substance diluent [2 mL syringe], 1 pack |

## **Supply Only**

From 1 November 2020 when a product is deleted from the Schedule it may now be available under new Supply Only rules. Supply Only items/brands are available on the Schedule for dispensing but not for prescribing, usually for a period of up to 12 months from when it is deleted.

Substitution of Supply Only items/brands with products flagged as "equivalent for substitution" still apply as specified in the Schedule at the time the script was written. Further information on Supply Only arrangements is available at [www.pbs.gov.au](http://www.pbs.gov.au)

### ***Supply Only commencing July 2021***

- |        |  |
|--------|--|
| 10279B | <i>Baraclude, BQ – ENTECAVIR</i> , entecavir 500 microgram tablet, 30  |
| 10353X | <i>Baraclude, BQ – ENTECAVIR</i> , entecavir 1 mg tablet, 30   |
| 10317B | <i>Roferon-A–INTERFERON ALFA-2A</i> , interferon alfa-2a 3 million units (11.111 microgram)/0.5 mL injection, 0.5 mL syringe |
| 10369R | <i>Roferon-A–INTERFERON ALFA-2A</i> , interferon alfa-2a 9 million units (33.333 microgram)/0.5 mL injection, 0.5 mL syringe |

### ***Advance Notices***

**1 August 2021**

#### ***Deletion – Brand***

- |        |  |
|--------|--|
| 10306K | <i>Valcyte, RO – VALGANCICLOVIR</i> , valganciclovir 450 mg tablet, 60 |
|--------|--|

## **Repatriation Pharmaceutical Benefits**

### **Additions**

#### ***Addition – Item***

- |        |  |
|--------|--|
| 12592R | <b>BANDAGE COMPRESSION</b> , bandage compression two layer bandage, 1 ( <i>Putter Pro 2 931685</i> )   |
| 12571P | <b>DRESSING HYDROACTIVE DEBRIDEMENT</b> , dressing hydroactive debridement dressing 4 cm round, 10 ( <i>HydroClean Plus 609602</i> )               |
| 12580D | <b>DRESSING HYDROACTIVE DEBRIDEMENT</b> , dressing hydroactive debridement dressing cavity 4 cm round, 10 ( <i>HydroClean Plus Cavity 609622</i> ) |
| 12562E | <b>DRESSING HYDROACTIVE DEBRIDEMENT</b> , dressing hydroactive debridement dressing 5.5 cm round, 10 ( <i>HydroClean Plus 609606</i> )             |
| 12563F | <b>DRESSING HYDROACTIVE DEBRIDEMENT</b> , dressing hydroactive debridement dressing 7.5 cm round, 10 ( <i>HydroClean Plus 609608</i> )             |
| 12564G | <b>DRESSING HYDROGEL SHEET</b> , dressing hydrogel sheet 12.5 cm x 12.5 cm, 5 ( <i>Hydrosorb Comfort 900723</i> )                                  |
| 12558Y | <b>DRESSING NON ADHERENT</b> , dressing non adherent 7.5 cm x 10 cm dressing, 10 ( <i>Atrauman Silicone 499561</i> )                               |
| 12600E | <b>DRESSING NON-ADHERENT ABSORBENT</b> , dressing non-adherent absorbent 10 cm x 10 cm, 10 ( <i>Zetuvit Plus 413710</i> )                          |
| 12593T | <b>DRESSING NON-ADHERENT ABSORBENT</b> , dressing non-adherent absorbent 10 cm x 20 cm, 10 ( <i>Zetuvit Plus 413711</i> )                          |
| 12599D | <b>DRESSING NON-ADHERENT ABSORBENT</b> , dressing non-adherent absorbent 20 cm x 40 cm, 10 ( <i>Zetuvit Plus 413715</i> )                          |
| 12591Q | <b>DRESSING WITH SILVER</b> , dressing with silver 10 cm x 10 cm tulle dressing, 10 ( <i>Atrauman Ag 499573</i> )                                  |
| 12596Y | <b>PSYLLIUM HUSK POWDER</b> , psyllium husk powder 3.4 g/7 g powder for oral liquid, 504 g ( <i>Metamucil Natural Granular</i> )                   |

---

**Addition – Brand**

- 2194L *Alendronate Plus D3 Sandoz, SZ – ALENDRONATE + COLECALCIFEROL*, alendronate 70 mg + colecalciferol 70 microgram (2800 units) tablet, 4
- 2224C *Alendronate Plus D3 Sandoz, SZ – ALENDRONATE + COLECALCIFEROL*, alendronate 70 mg + colecalciferol 140 microgram (5600 units) tablet, 4
- 4233T *Finasteride Mylan 5, AF – FINASTERIDE*, finasteride 5 mg tablet, 30
- 4592Q *Gabapentin Sandoz, SZ – GABAPENTIN*, gabapentin 300 mg capsule, 100
- 4593R *Gabapentin Sandoz, SZ – GABAPENTIN*, gabapentin 400 mg capsule, 100
- 4279F *HYOSCINE BUTYLBROMIDE MEDSURGE, DZ – HYOSCINE BUTYLBROMIDE*, hyoscine butylbromide 20 mg/mL injection, 5 x 1 mL ampoules
- 4596X *Apo-Tadalafil, TX – TADALAFIL*, tadalafil 10 mg tablet, 4
- 4596X *Cidala, RW – TADALAFIL*, tadalafil 10 mg tablet, 4
- 4596X *Tadalafil GH, GQ – TADALAFIL*, tadalafil 10 mg tablet, 4
- 4597Y *Apo-Tadalafil, TX – TADALAFIL*, tadalafil 20 mg tablet, 4
- 4597Y *Cidala, RW – TADALAFIL*, tadalafil 20 mg tablet, 4
- 4597Y *Tadalafil GH, GQ – TADALAFIL*, tadalafil 20 mg tablet, 4
- 4070F *Apo-Tamsulosin SR, TX – TAMSULOSIN*, tamsulosin hydrochloride 400 microgram modified release tablet, 30
- 4070F *Blooms the Chemist Tamsulosin SR, IB – TAMSULOSIN*, tamsulosin hydrochloride 400 microgram modified release tablet, 30

**Alterations****Alteration – Manufacturer Code**

|       |  | <i>From</i> | <i>To</i> |
|-------|--|-------------|-----------|
| 4046Y | <i>Solaraze 3% Gel – DICLOFENAC</i> , diclofenac sodium 3% gel, 25 g | FK          | YN        |